 Connection
Hitoshi Irabu to Receptors, Tumor Necrosis Factor, Type II
This is a "connection" page, showing publications Hitoshi Irabu has written about Receptors, Tumor Necrosis Factor, Type II.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.269 |
|
|
|
-
Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy. Pediatr Res. 2020 12; 88(6):934-939.
Score: 0.157
-
Mizuta M, Shimizu M, Irabu H, Usami M, Inoue N, Nakagishi Y, Wada T, Yachie A. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology (Oxford). 2021 01 05; 60(1):231-238.
Score: 0.042
-
Usami M, Shimizu M, Mizuta M, Inoue N, Irabu H, Sakumura N, Nakagishi Y, Yachie A. Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus. Clin Immunol. 2019 11; 208:108255.
Score: 0.038
-
Shimizu M, Inoue N, Kuroda M, Irabu H, Takakura M, Kaneda H, Sugimoto N, Ohta K, Yachie A. Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Clin Exp Nephrol. 2017 Dec; 21(6):1083-1087.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|